3 results match your criteria: "Hôpitaux Universitaires Paris Centre (APHP) and University Paris Descartes (EA2511)[Affiliation]"
DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT).
J Asthma
October 2020
Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen University, Copenhagen, Denmark.
Adherence and inhaler technique are often suboptimal in asthma and chronic obstructive pulmonary disease (COPD). New inhalers have been developed to improve these determinants of treatment effectiveness. We assessed treatment adherence, satisfaction, and ease of use of DuoResp Spiromax among SPRINT study participants.
View Article and Find Full Text PDFObjectives: Budesonide/formoterol (BF) Spiromax is an inhaled corticosteroid/long-acting β-agonist fixed-dose combination (FDC) inhaler, designed to minimise common inhaler errors and provide reliable and consistent dose delivery in asthma and chronic obstructive pulmonary disease (COPD). We evaluated non-inferiority of BF Spiromax after changing from another FDC inhaler, compared with continuing the original inhaler.
Methods: Patients with asthma and/or COPD who switched to BF Spiromax were matched (1:3) with non-switchers.
Personalised medicine: are we ready?
Eur Respir Rev
September 2017
Respiratory and Intensive Care Medicine, Cochin Hospital, Hôpitaux Universitaires Paris Centre (APHP) and University Paris Descartes (EA2511), Paris, France
http://ow.ly/VGGE30eYTmT
View Article and Find Full Text PDF